Wow, that's very close to the 90% I arrived at after a detailed analysis.I will share my analysis at some point, but suffice to say it's very unlikely Neuren won't get at least one new FDA approved treatment from NNZ-2591, and most likely they will get many. In the world of drug development NNZ-2591, for a whole list of reasons, is as close to a sure thing as it's possible to get.There was definite risk before the Trofinetide Phase 3 results.But for NNZ-2591 I am personally very relaxed. The risk of failure is low.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.63 |
Change
-0.070(0.42%) |
Mkt cap ! $2.095B | |||
| Open | High | Low | Value | Volume |
| $16.68 | $16.86 | $16.51 | $4.012M | 240.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 982 | $16.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.66 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |